Geoffrey Gladstein

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Abatacept in the treatment of patients with psoriatic arthritis: Results of a six‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II trial

Philip J. Mease, Mark C. Genovese, Geoffrey Gladstein et al. · Arthritis & Rheumatism · 2010 · 296 citations

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Atul Deodhar, Alice B. Gottlieb, Wolf‐­Henning Boehncke et al. · The Lancet · 2018 · 181 citations

Rheumatology, Medicine, Systemic Treatment +9

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)

Jeffrey Kaine, Geoffrey Gladstein, Ingrid Strusberg et al. · Annals of the Rheumatic Diseases · 2011 · 73 citations · Full text